Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
Date:5/30/2013

SAN FRANCISCO, May 30, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 Jefferies Global Healthcare Conference in New York at the Grand Hyatt Hotel on Tuesday, June 4, 2013 at 9:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until July 8, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In a
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... -- UBM Medica US announces that Endocrinology Network , ... who treat patients with type 2 diabetes ... insulin .  Nearly all patients with ... – daily injections of one or more insulin formulations—to ... of pancreatic beta cells. Insulin is a very effective ...
(Date:10/17/2014)...  China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... approval from the China Food and Drug Administration ... complex concentrate ("PCC") at its Shandong Taibang facility. ... production facility for Good Manufacturing Practices ("GMP") compliance ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... UNITED NATIONS, New York (PRWEB) October 19, 2014 ... the United Nations Population Fund, welcomes news of a ... release of the more than 200 girls who were ... Girls. "These girls have languished in captivity long enough, ... their families, schools and communities," stated Dr. Osotimehin. , ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... who do not have osteoporosis , , FRIDAY, Jan. 18 ... downplay the risks of prescribing bone-strengthening drugs for women ... osteoporosis, a new report claims. , Drugs such as ... fractures of women with osteoporosis, according to the article ...
... funding promotes diabetes care improvement at a community-level, ... throughout the,U.S. in implementing and evaluating models for ... Business Coalition on Health,(NBCH) announced the recipients of ... for NBCH member coalitions -- intended to support ...
... JOSE, Calif., Jan. 18 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of venous reflux disease, today,announced ... and,Vice President of Finance and Administration., Mr. Osborne ... in,various senior leadership roles. Mr. Osborne had served as ...
... M.D., distinguished professor of microbiology and immunology and of ... of Yeshiva University, has received the second annual Marshall ... a special ceremony at the medical school. , ... long-time member of the Einstein faculty, Marshall S. Horwitz, ...
... Antipolis, France ---Bridging the unacceptable gap between what is ... the prevention of cardiovascular disease is how Prof Guy ... of the European Society of Cardiology (ESC), summarises the ... , Creating incentives for people to make healthy ...
... to detect surface cancers quickly and painlessly using ... composition has been developed by a QUT PhD ... School of Physical and Chemical Sciences has developed ... diagnose cervical and skin cancers. , Bioimpedance measures ...
Cached Medicine News:Health News:Bone-Strengthening Drugs May Be Overprescribed 2Health News:Bone-Strengthening Drugs May Be Overprescribed 3Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 2Health News:National Business Coalition on Health Awards Grants to 14 Coalitions for Diabetes Quality Programs 3Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Einstein honors Dr. Stanley Nathenson with Marshall S. Horwitz Faculty Prize for Research Excellence 2Health News:European Summit on Cardiovascular Disease Prevention 2
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
... high resolution 1640 x 1280 digital ... - digital achieves new levels of ... use. Now supplied complete with Kowa's ... image and patient management software this ...
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: